Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
December 18, 2014, 12:44:10 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 649750
  • Total Topics: 49592
  • Online Today: 284
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Peregrine Inc. presents results from HCV/ HIV Phase 1b trial  (Read 2166 times)

0 Members and 1 Guest are viewing this topic.

Offline J220

  • Member
  • Posts: 587
Peregrine Inc. presents results from HCV/ HIV Phase 1b trial
« on: April 07, 2011, 02:31:20 AM »
Peregrine Inc. presents results from HCV/ HIV Phase 1b Bavituximab trial. They report:

 "Transient antiviral activity (maximum reduction in HCV and/or HIV viral load of  > 0.5 log from baseline) was observed in all dose levels."

Also:

"Signs of on therapy HCV and HIV antiviral activity were observed in all treatment groups."

Here's the poster link (in PDF): http://www.peregrineinc.com/images/stories/pdfs/easl_hcv.pdf

Looks good so far! Could this be it, could this be what we've all been waiting for???
« Last Edit: April 07, 2011, 02:42:04 AM by J220 »
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

Offline MitchMiller

  • Member
  • Posts: 482
Re: Peregrine Inc. presents results from HCV/ HIV Phase 1b trial
« Reply #1 on: April 09, 2011, 04:09:50 PM »
The web site implies the test went for a year.  .5 log reduction for HIV is not commercially viable.  Seems like a failure to me.

I believe the standard expectation of current ARVs is patients should achieve a 1-log reduction in viral load within 1 to 2 months of beginning therapy.

Offline J220

  • Member
  • Posts: 587
Re: Peregrine Inc. presents results from HCV/ HIV Phase 1b trial
« Reply #2 on: April 10, 2011, 12:18:52 AM »
The web site implies the test went for a year.  .5 log reduction for HIV is not commercially viable.  Seems like a failure to me.

I believe the standard expectation of current ARVs is patients should achieve a 1-log reduction in viral load within 1 to 2 months of beginning therapy.

You are forgetting these are phase I results, designed to test mainly for safety and tolerability, not final effectivness- that will  come later at higher dosages. So right now, to see some therapeutic effects at even these low doses, when they have not reached maximum tolerated dose or maximum effective dose (MTD and MED), this is why this is significant.
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

Offline Cosmicdancer

  • Member
  • Posts: 154
Re: Peregrine Inc. presents results from HCV/ HIV Phase 1b trial
« Reply #3 on: April 10, 2011, 10:38:40 AM »
Good point J220.  The highest dosing level was 6 mg, given intravenously once a week for 8 weeks.  That sounds quite low, compared to the hundreds of mg's most of us take daily of ARVs.  Only 1 of the 6 patients reported any adverse events at that level (asthma), which may have been a pre-existing condition.  At the 6 mg dose, 5 of the 6 patients (83%) had at least a .4 log decline in HIV viral load.  At the 3 mg dose, 3 of the 9 patients (33%) had at least a .4 log decline in HIV viral load. 

The study lasted for about 4 months, there was a 4 week screening period, 8 weekly injections, and then a one month follow up period.  They noted that "Bavituximab did not exhibit appreciable accumulation following multiple-dose administration once weekly for eight weeks". 

One of the conclusions of the study was that the "data supported the initiation of a 12-week phase 2 study to determine the early virological response (EVR) rate of bavituximab given in combination with ribavirin to treatment naive patients with Hep C."  It doesn't mention a phase 2 study in people with HIV, although the data supports doing further study at higher doses.
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
June, 2008 - undetectable, 612 cd4
January, 2009 - undetectable, 670 cd4
May, 2009 - undetectable, 593 cd4
Sept, 2009 - 83 vl, 763 cd4, 34%
Dec, 2009 - undetectable, 889 cd4, 32%
April, 2010 - undetectable, 860 cd4, 31%
October, 2010 - undetectable, 800 cd4, 38%
April, 2011 - undetectable, t-cell test not done
October, 2011 - undetectable
April, 2012 - undetectable, 850 cd4, 39%
November, 2012 - undetectable, 901 cd4, 41%
April, 2013 - undetectable, 846 cd4, 36%
October, 2013 - undetectable
May, 2014 - undetectable, 784 cd4, 48%
October, 2014 - UD, 1084 cd4, 48%

Offline freaky_dream

  • Member
  • Posts: 132
  • mmm
Re: Peregrine Inc. presents results from HCV/ HIV Phase 1b trial
« Reply #4 on: April 11, 2011, 04:37:33 AM »
wrong thread...

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.